

Experimental report

02/02/2016

Proposal: TEST-2335

Council: 4/2014

Title: IAPP interaction with bilayer

Research area:

This proposal is a new proposal

Main proposer: Lionel PORCAR

Experimental team: Lucas ANTONY
Patrick HARRISON
Irena KIESEL
Anne MARTEL
Yuri GERELLI
Giovanna FRAGNETO

Local contacts: Giovanna FRAGNETO

Samples: Protein IAPP
Fragments + lipids

| Instrument | Requested days | Allocated days | From | To |
|------------|----------------|----------------|--------------------------|--------------------------|
| FIGARO | 2 | 3 | 24/07/2014 04/12/2014 | 26/07/2014 05/12/2014 |

Abstract:

Experimental report for proposals

TEST2358, TEST2335, 8-02-742 and 8-02-688

Martel A., Gerelli Y., Porcar L., Fragneto G.

These beam times were part of a large study including Neutron reflectometry (NR), SANS and laboratory techniques to investigate the interaction of IAPP fragments with POPC bilayers. IAPP is the peptide involved in β -cell depletion leading to the development of Diabetes Mellitus type 2. In order to understand the interaction of the peptide with cell membrane and its consequences, we used SANS and NR. The peptides we choose are depicted table 1: IAPP human peptide (hIAPP₁₋₃₇) has been splitted in two halves: the N-terminal half (hIAPP₁₋₂₀) is suspected to interact with lipids and the C-terminal half (hIAPP₂₃₋₃₇) is very aggregation-prone and has been shown to fold into a beta-sheet and form the spine of the amyloid fibers. The rat homologs (rIAPP₁₋₃₇, rIAPP₁₋₂₀ and rIAPP₂₃₋₃₇) have been used as non-amyloidogenic and non-toxic controls. Human and rat peptides differ by 6 positions which only one is in the C-terminal half. The chimeric peptide rIAPP₁₋₃₇R18H associating the human N-terminal half and the rat C-terminal half has also been analysed.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------------|---|------|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|-------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|--|
| | | 1-37 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1-20 | | | | | | | | | | | | | | | | | | | | | 23-37 | | | | | | | | | | | | | | | | |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | |
| Human | ◇ | K | C | N | T | A | T | C | A | T | Q | R | L | A | N | F | L | V | H | S | S | N | N | F | G | A | I | L | S | S | T | N | V | G | S | N | T | Y | |
| Rat _{R18H} | △ | K | C | N | T | A | T | C | A | T | Q | R | L | A | N | F | L | V | H | S | S | N | N | L | G | P | V | L | P | P | T | N | V | G | S | N | T | Y | |
| Rat | □ | K | C | N | T | A | T | C | A | T | Q | R | L | A | N | F | L | V | R | S | S | N | N | L | G | P | V | L | P | P | T | N | V | G | S | N | T | Y | |

Table 1- Sequence of the peptides used in this study: the hIAPP₁₋₃₇: the human peptide (top) and the rIAPP₁₋₃₇, the rat peptide (bottom) are split in two fragments: the N-terminal from amino acid 1 to 20 (hIAPP₁₋₂₀ and rIAPP₁₋₂₀) and the C-terminal from amino acid 23 to 37 (hIAPP₂₃₋₃₇ and rIAPP₂₃₋₃₇). The mismatches between the human and rat sequences are marked in grey. The sequence of the chimeric peptide rIAPP₁₋₃₇R18H is in the middle.

The ability of each peptide to permeate a POPC bilayer has been measured on the PSCM set up for Electrophysiology on DIB. Figure 1 shows the results of these measurements. They show that hIAPP₁₋₃₇ is able to permeate the model membrane but hIAPP₁₋₂₀ and rIAPP₁₋₃₇R18H are much more efficient than the full length human peptide. An interpretation of these results is that the N-terminal half of the human peptide is responsible for lipid bilayer disturbance and that the amyloidogenicity of the C-terminal half inhibits it. The other peptides: the 3 rat peptides and the human C-terminal half, does not have any effect on the POPC bilayer conductance.




Figure 1- Conductance of a POPC bilayer plotted as a function of time. The black arrow figures the time point of injection of the peptides: full length (green), fragment 1-20 (red) and fragment 23-37 (blue). The left plot concerns human-derived peptides and the right plot, rat-derived peptides, including the chimeric rAPP₁₋₃₇R18H (grey). When the amplifier saturated, the tension was decreased from 10mV to 2 mV to pursue the recording.

Structural characterization of the POPC bilayer disturbed by the peptides has been performed by NR with the POPC membrane deposited on the surface of a Silicon crystal on top of the buffer chamber for eventual aggregates to be discarded from the interface by gravity. Buffers with various D₂O content were used for contrast variation and the curves were simultaneously fitted using Aurora software. The SLD profiles resulting from these fittings are shown by figure 2. We observed a dramatic lipid depletion following the injection of hAPP₁₋₂₀ nearby the bilayer. A less pronounced effect was observed with hAPP₁₋₃₇ which apparently inserts through the first leaflet of the bilayer, mainly amongst the headgroups, as well as rAPP₁₋₃₇R18H which insertion in the first leaflet is accompanied with lipid depletion. These results confirm that the N-terminal half, in particular the histidine18, is crucial for the interaction of the peptide with a POPC bilayer. They also strongly suggest that lipid depletion could be the mechanism of bilayer permeation.




Figure 2- SLD profiles of the interface obtained from fitting the neutron reflectometry spectra recorded after peptide injection, at different contrasts: 0% D₂O in blue, 38% D₂O in green, 52% D₂O in yellow, 66% D₂O in black, 100% D₂O in red. The grey star markers are the SLD profiles of bilayers before peptide injection in 100% D₂O buffer. The capital letters H or D before the peptide and lipid names stand for Hydrogenated (Natural deuterium abundance) or Deuterated.

This hypothesis raises the question of the fate of the lipids removed from the bilayer. The structural analysis of aggregates of hIAPP₁₋₃₇ formed in presence or absence of POPC vesicles have been carried out by contrast-variation SANS (D22). The results are presented on figure 3 as the square root of the intensity extrapolated at Q=0 angle as a function of D₂O content of the buffer. This analysis shows that the presence of POPC vesicles during hIAPP₁₋₃₇ aggregation changes the aggregates match point from 39% to 26% D₂O, which would correspond to an incorporation of three lipid molecules per peptide within the aggregates. Furthermore, the Intensity scattered by the lipid-peptides co-aggregates never reaches 0, which suggest that within the aggregates, the lipids and the peptides segregate in two phases rather than mixing intimately.




Figure 3- Matchout plots from SANS measurements of hIAPP₁₋₃₇ aggregates formed in absence (A) or presence (B) of POPC. The square root of the neutron scattering intensity at Q = 0, normalized by the sample concentration, is plotted as a function of the D₂O content of the solvent.

All together, these results enable us to propose a cytotoxicity mechanism in which the N-terminal half of hIAPP₁₋₃₇ would insert in the lipid bilayer and extract a large amount of lipids from it leading to membrane permeation. The amyloid aggregation could be an inhibitory mechanism selected as a rescue system to delay the onset of the disease.

A publication presenting these results and interpretation is in preparation.